Research and Markets: Type 2 Diabetes Therapeutics Pipeline Review 2015 - Featuring Over 200 Companies

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/7h7fql/type_2_diabetes) has announced the addition of the "Type 2 Diabetes - Pipeline Review, H1 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Type 2 Diabetes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 2 Diabetes and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Type 2 Diabetes Overview
  3. Therapeutics Development
  4. Type 2 Diabetes - Therapeutics under Development by Companies
  5. Type 2 Diabetes - Therapeutics under Investigation by Universities/Institutes
  6. Type 2 Diabetes - Pipeline Products Glance
  7. Type 2 Diabetes - Products under Development by Companies
  8. Type 2 Diabetes - Products under Investigation by Universities/Institutes
  9. Type 2 Diabetes - Companies Involved in Therapeutics Development
  10. Type 2 Diabetes - Therapeutics Assessment
  11. Drug Profiles
  12. Small Molecules to Inhibit CDK5 for Type 2 Diabetes - Drug Profile
  13. Type 2 Diabetes - Recent Pipeline Updates
  14. Type 2 Diabetes - Dormant Projects
  15. Type 2 Diabetes - Discontinued Products
  16. Type 2 Diabetes - Product Development Milestones
  17. Appendix

Companies Mentioned

  • ActogeniX NV
  • Addex Therapeutics Ltd
  • Advinus Therapeutics Ltd.
  • Aegis Therapeutics, LLC
  • AFFiRiS AG
  • AlbireoPharma
  • Alchemia Limited
  • Alize Pharma SAS
  • Allozyne, Inc.
  • AlphaMab Co., Ltd
  • Ambrx, Inc.
  • Amgen Inc.
  • Anchor Therapeutics, Inc.
  • AntriaBio, Inc.
  • Ardelyx, Inc.
  • Arena Pharmaceuticals, Inc.
  • Arisaph Pharmaceuticals, Inc.
  • Array BioPharma Inc.
  • Arrien Pharmaceuticals, LLC
  • Artery Therapeutics, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • AUS Bio Limited
  • Avaxia Biologics, Inc.
  • Bayer AG
  • Betagenon AB
  • Biocon Limited
  • Biodel Inc.
  • Biogenomics Limited
  • BioRestorative Therapies, Inc.

For more information visit http://www.researchandmarkets.com/research/7h7fql/type_2_diabetes

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals